Studies of antibiotic resistance within the patient, hospitals and the community using simple mathematical models

D. J. Austin and R. M. Anderson

Wellcome Trust Centre for the Epidemiology of Infectious Diseases, University of Oxford, South Parks Road, Oxford OX1 3PS, UK (daren.austin@zoo.ox.ac.uk)

The emergence of antibiotic resistance in a wide variety of important pathogens of humans presents a worldwide threat to public health. This paper describes recent work on the use of mathematical models of the emergence and spread of resistance bacteria, on scales ranging from within the patient, in hospitals and within communities of people. Model development starts within the treated patient, and pharmacokinetic and pharmacodynamic principles are melded within a framework that mirrors the interaction between bacterial population growth, drug treatment and the immunological responses targeted at the pathogen. The model helps identify areas in which more precise information is needed, particularly in the context of how drugs influence pathogen birth and death rates (pharmacodynamics). The next area addressed is the spread of multiply drug-resistant bacteria in hospital settings. Models of the transmission dynamics of the pathogen provide a framework for assessing the relative merits of different forms of intervention, and provide criteria for control or eradication. The model is applied to the spread of vancomycin-resistant enterococci in an intensive care setting. This model framework is generalized to consider the spread of resistant organisms between hospitals. The model framework allows for heterogeneity in hospital size and highlights the importance of large hospitals in the maintenance of resistant organisms within a defined country. The spread of methicillin resistant Staphylococcus aureus (MRSA) in England and Wales provides a template for model construction and analysis. The final section addresses the emergence and spread of resistant organisms in communities of people and the dependence on the intensity of selection as measured by the volume or rate of drug use. Model output is fitted to data for Finland and Iceland and conclusions drawn concerning the key factors determining the rate of spread and decay once drug pressure is relaxed.

Keywords: antibiotic resistance; transmission dynamics; epidemiology; pharmacodynamics; nosocomial infection; mathematical models

1. INTRODUCTION

Genetic diversity is a characteristic of microbes, whether their lifestyle is free-living or parasitic. The last few years has seen rapid advances in our understanding of the genetic diversity within bacterial populations and the structures of the genetic codes of a series of important species, including some major pathogens of humans such as Mycobacterium tuberculosis (Cole et al. 1998). One aspect of this genetic diversity and the potential for rapid evolution within bacteria that is of major public health significance worldwide is the emergence and spread of antibiotic resistance in a wide variety of organisms that infect humans, and birds plus mammal species within the agricultural industry. Today many view the evolution and spread of antibiotic resistance as the major public health crisis of the late part of this century, with the evolution of bacteria within hospital settings that are resistant to all major antibiotics a distinct possibility in the very near future.

The study of antibiotic resistance is a field that has largely been the preserve of the microbiologist and the infectious disease clinician responsible for the care of patients with bacterial infections. Until recently, most have had confidence in the pharmaceutical industry to keep one step ahead of the microbe in terms of producing new antibiotics that can combat infection by organisms resistant to the previous generations of drugs. To date that has certainly been the case. However, the rate of discovery of new compounds has slowed considerably over the past three decades, in part due to the very high costs of research, development and testing prior to the successful launch of a new antibiotic. In discussions of how best to combat resistance or how to slow its spread, the debates have largely centred on the microbiological and clinical issues. Very few papers in this important field address the key population genetic issues that underpin an understanding of the evolution and spread of resistant organisms (Björkman et al. 1998; Stilianakis et al. 1998; Blower et al. 1998; Levin et al. 1997; Austin et al. 1997a,b; Bonhoeffer et al. 1997; Schrag et al. 1997; Lenski 1997; Lenski et al. 1994; Massad et al. 1993). An even smaller number attempt to meld current understanding of the transmission dynamics of bacteria in human communities...
(including hospitals), with the key population genetic factors (Levin et al. 1997; Austin et al. 1999; Bonhoeffer et al. 1997). The number of publications that meld these two areas, in combination with an understanding of the mechanisms of the evolution of resistance, patterns of drug consumption and the pharmacokinetics and pharmacodynamics of defined drugs and pathogens, can be counted on one hand (Lipsitch & Levin 1997; Austin et al. 1998b).

The general issue is that an interdisciplinary approach is needed to interpret correctly current patterns of evolution and spread, plus address the issue of how best to manage antibiotic resistance in both the healthcare and community settings. Techniques and concepts from a wide variety of different fields must be harnessed, such as those in pharmacology, microbiology, population genetics and epidemiology. A powerful template to merge the methods and concepts of these different fields of scientific study can be constructed by the sensible use of simple and complex mathematical models of the key biological processes. The case for the use of a mathematical framework is made even more compelling by the strong existing traditions for the use of mathematical methods in the fields of pharmacology, population genetics and epidemiology.

In this paper we present some recent research that melds different components of these various fields to address problems at a series of different levels of study. These include the evolution of resistance within the treated host, the spread of resistance within and between hospital settings, and the epidemiology and evolution of resistance in communities of people. Our approach is the use of simple mathematical templates and our aim is to shed light on the key factors that control observed patterns of antibiotic resistance and how drug use can be tailored to slow the likelihood of evolution and rapid spread. A central problem in management is the key principle that the stronger the selective pressure, the more rapid will be the pace of evolution to meet this pressure. The frequency of antibiotic resistant organisms in a defined population of bacteria is invariably related to past or current patterns of drug use. To alter frequency it is necessary to change the direction of selection. How best to do this will depend on the precise details of host, bacteria and drug. However, a precise mathematical template for study helps identify what needs to be measured and the key processes determining observed pattern.

2. WITHIN-HOST MODELS OF INFECTION AND ANTIBIOTIC TREATMENT

The use of mathematical models for the analysis of viral infections such as HIV has resulted in considerable advances in our understanding of both disease progression and the impact of drug therapy (Ho et al. 1995; Wei et al. 1993; Bonhoeffer et al. 1996; Austin et al. 1999b). In the case of bacterial infections, where within-host dynamics is not so easily measurable, there have been fewer advances (Lipsitch & Levin 1997). In the pharmacological research literature, mathematical models of drug absorption and elimination kinetics have been widely used. This field of study is referred to as pharmacokinetics (Rowland & Tozer 1995; Austin et al. 1998b). A large amount of data are available on the pharmacokinetics of antibiotic agents which can be usefully employed in mathematical models of bacterial infection and treatment. The effect of an antibiotic on the target pathogen usually correlates with the concentration of the drug in the habitat of the pathogens. The study of dynamical response of the infectious agent in the presence of the drug is termed pharmacodynamics (Lowdin et al. 1998; Aeschlimann et al. 1998; Berg et al. 1996; Hyatt et al. 1995; Drusano et al. 1993) and provides the link between pharmacokinetics and models of within host pathogen population dynamics (Austin et al. 1998b).

(a) Pharmacokinetics and pharmacodynamics

Antibiotics may be administered either orally, intramuscularly or intravenously, and the eventual concentration of active drug at the site of infection will be determined by the dose, the route of administration and the dosage regimen. Dosage regimens are designed to maintain drug concentrations at therapeutic levels, and must balance issues of both toxicity and efficacy (Rowland & Tozer 1995). For simplicity, we concentrate on changes in the concentration, \(C(t)\), of a single antibiotic given at a dose, \(D\), to a host with volume of distribution \(V\) such that \(C_0 = D/V\), where \(C_0\) is the initial concentration. If absorption is rapid (i.e. can be ignored) or the antibiotic is given intravenously, and elimination follows first-order kinetics (as is common during the early stages of elimination), then the plasma concentration at time \(t\) is determined by

\[
\frac{dC}{dt} = -kC, \quad (1)
\]

\[
C(t) = C_0 \exp(-kt), \quad (2)
\]

where \(k\) is the elimination constant and the half-life of the drug is \(t_{1/2} = \ln(2)/k\). Assuming doses are given at discrete times \(t = 0, t = \tau, t = 2\tau\), etc. then the concentration immediately after \(i\) doses will be

\[
C_i = C_0 \left( \frac{1 - r^i}{1 - r} \right), \quad (3)
\]

where \(r = \exp(-k\tau)\) is the decay factor. After several doses the regimen reaches equilibrium and the concentration \(C(t)\) lies between the limits \(C(t) \leq C_{t} \leq C_{\text{max}}\) where \(C_{\text{max}} = C_0 R\) and \(R = 1/(1 - r)\) is called the accumulation factor. Typically, the impact of a drug in a defined pathogen population saturates with increasing drug concentration. Suggested reasons for this saturation include metabolic effects such as enzyme production and a fixed number of sites where a drug can act on the invading organism. We use the so-called \(E_{\text{max}}\) saturating model, where if \(E\) is the effect of the drug (e.g. per capita death rate of the bacteria due to the action of the drug at concentration \(C\)), then

\[
E(C) = \frac{E_{\text{max}} C^n}{C^n + C_{\text{50}}^n}, \quad (4)
\]

Hence, \(E_{\text{max}}\) denotes the maximum effect, \(C_{\text{50}}\) the concentration at half effect and \(n\) is a shape factor denoting the slope of the curve.
grown in varying concentrations of drug either in vivo (density dependence) and 
Pseudomonas aeruginosa of rate, effect involve growth curves, in which an organism is
antibiotic effect, \(C\) where
population growth of bacteria. If \(\lambda(N)\) is the net growth rate of a bacteria if \(N\) organisms are present (allowing for density dependence) and \(\alpha(C)\) the bacterial kill rate at drug concentration \(C\), then in the absence of any post antibiotic effect,
\[
\frac{dN}{dt} = \lambda(N) - \alpha(C)N. \tag{5}
\]
For in vitro studies \(\lambda(N) = \lambda V(1-N/K)\) where \(K\) is a carrying capacity determined by the experiment. This simple model can be used to fit experimental data providing a concentration–kill rate pharmacodynamic curve (figure 1). In this dynamical model a minimum inhibitory concentration (MIC) can be defined as the concentration which just inhibits bacterial growth i.e. \(\alpha(C) = \lambda\), or equivalently,
\[
\text{MIC} = (1 - e)^{-1/\lambda C_{50}} \tag{6}
\]
where \(\epsilon = \lambda/\alpha\) is the ratio of maximum kill rate to net growth rate. For bacteriostatic antibiotics (e.g. macrolides) the net growth rate becomes a function of drug concentration, \(\alpha(C)\), however the conclusions from our analyses will remain unchanged.

The effects of antibiotic resistance will manifest themselves via the pharmacodynamics of antibiotic action. Conventional measures of antibiotic resistance take the form of MIC determination and categorization via breakpoints. An increased MIC may be a result of any combination of three factors determined by the experiment. Second, \(C_{50}\) may increase, thereby shifting the overall curve to the right in a linear manner. Second, \(\epsilon\) may decrease thereby reducing the peak bactericidal kill rate, \(\alpha\). Third, the shape function, \(n\) may increase (although this effect will be minimal). Since pharmacodynamic studies have thus far tended to focus on sensitive organisms, the precise pharmacodynamic effects of antibiotic resistance remain uncertain (figure 2). It is, however, important that these effects be quantified, as they have profound influences on the usefulness of a drug. For example, if \(C_{50}\) increases then the saturating bactericidal kill rate \(\alpha\) can still be reached (for a sufficiently high dose, \(D\)), hence clinical improvement may be seen by doubling the dose of amoxicillin for infections with reduced sensitivity (as proposed in Spain).

If, however, bactericidal activity is reduced, then no increase in dose will ever be able to compensate for the loss of sensitivity and the clinical lifetime of the drug cannot be increased. Typical mechanisms for antibiotic resistance may include efflux whereby the drug is pumped out of the cell (e.g. Pseudomonas aeruginosa resistance to imipenem (Livermore 1992)), altered target site (e.g. penicillin-binding protein) and deactivation of the drug by enzymes (e.g. beta-lactamase resistance) (see Salyers & Whitt (1994) for further details). For drug efflux the first pharmacodynamic effect would appear most likely, the drug is at a reduced concentration within the cell. Where the target site is altered, increasing concentration will obviously have little effect. When a drug is broken down by enzyme activity, increasing the number of sites can restore sensitivity, as has been demonstrated by the use of clavulanic acid added to amoxicillin (Nalwani & Wood 1993).

(b) Mathematical models of antibiotic therapy
Pharmacodynamic models provides the ideal template for constructing models of antibiotic therapy and the emergence of resistance. Once the concentration–kill rate curve is known, equation (5) can be solved under given assumptions, such as exponential growth of the bacteria in the absence of a drug, multiple dosing, multiple strains and the influence of acquired immunity. We use the complete \(E_{max}\) model throughout and begin by considering the effects of multiple dosing during exponential growth (Lipsitch & Levin 1997). Dividing equation (5) by \(N\), gives the simplified form
\[
\frac{d\ln N}{dt} = \lambda - \frac{\alpha C_0^\epsilon \exp(-kn(t-t_0))}{C_{50} + C_0 \exp(-kn(t-t_0))}. \tag{7}
\]
which has the general solution
\[ N(t) = N(t_0) \exp(\lambda t) \left( \frac{C_{b0} + C_{b0}' \exp(-k_n(t-t_0))}{C_{b0} + C_{b0}'} \right)^{a/k_n}. \] (8)

If treatment occurs at discrete times (as in the multiple dosing regimen), then the change in \( \ln N_i \) of penicillin given every 6 h (500 mg) is given by
\[ A \ln N_i = \lambda \tau + \frac{\alpha}{k_n} \ln \left( \frac{C_{b0}(1-r)^n + C_{b0}'(1-r)^n}{C_{b0}(1-r)^n + C_{b0}'(1-r)^n} \right), \] (9)

Therapeutic regimens require that \( A \ln N_i \leq 0 \) (as an absolute minimum), which gives a threshold concentration \( C_{b0} \geq C_{b0} \) for a given decay parameter, \( r = \exp(-\lambda \tau) \),
\[ C_{b0} = \text{MIC} \left( \frac{(1-r)(1-r^n)}{r^n - r} \right)^{1/n}, \] (10)
depending on dose \( i \). For the first dose
\[ C_{b0}(i) = \text{MIC} \left( \frac{(1-r)(1-r^n)}{r^n - r} \right)^{1/n}, \] (11)
and at equilibrium \( i \to \infty \) \( C_{b0}(\infty) = C_{b0}(0)/R \). For example, suppose an antibiotic is given every half-life \( \tau = 2 \) and \( \epsilon = 0.5 \) (i.e. \( \text{MIC} = C_{b0} \) and \( n = 1 \). For the first dose \( C_{b0}(0) = \text{MIC}\sqrt{2} \) for therapeutic benefit, whereas once equilibrium is reached \( C_{b0}(\infty) = \text{MIC}/2 \).

Figure 3 shows the effect of multiple dosing on the pharmacodynamics of imipenem acting against \( P. \text{aeruginosa} \) (MIC = 1 mg l\(^{-1}\) and 10 mg l\(^{-1}\)). Elimination of the antibiotic reduces the kill rate from a peak (determined by both the dose and the MIC), and dosing returns the kill rate back up the curve. Since the concentration is plotted on a log scale and elimination is assumed to be first order (i.e. exponential), the length of the curve is proportional to time. Therapeutic regimens must keep the kill rate, \( \alpha(C) \), above the net growth rate, \( \lambda \), of the bacterium, which is shown for the sensitive strain (MIC = 1 mg l\(^{-1}\)). The resistant strain (MIC = 10 mg l\(^{-1}\)) will however show net growth because the dose (and hence \( C_{b0} = D/V \)) is below the minimum required for therapeutic activity, \( C_{b0} \).

(i) **Dose splitting: the effect of multiple dosing**

Dosage regimens are typically expressed in the form \( C_{b0}, \tau \) (i.e. a concentration, \( C_{b0} \), given every time period \( \tau \)). 500 mg of penicillin given every 6 h (500 gq) could equally be administered as 250 mg every 3 h (250gq). We write this as \( a/C_{b0} \tau \) where \( a \leq 1 \). If a regimen is subdivided into \( 1/\mu \) subdoses at intervals \( \tau' = \tau/\mu \) then the total log reduction in bacteria, \( A \ln N(a) \) is given by
\[ A \ln N(a) = A \ln N(a)|_{\tau = \tau'} + A \ln N(a)|_{\tau = 2\tau'} + \ldots + A \ln N(a)|_{(1-a)r^n/\tau' = a}. \] (12)

Summing individual terms using equation (9) gives a total log reduction

\[ \phi \text{Trans. R. Soc. Lond. B} \] (1999)
growth) then the exact solution of these equations is possible:

\[ N(t) = N(0) \exp(\lambda t) \exp(-x t + x(1 - \exp(-\mu t))/\mu), \]  

\[ I(t) = I_0(1 - \exp(-\mu t)), \]

where \( I_0 = A_0/\mu \) is the maximum immune response and \( x = \gamma A_0/\lambda \) is the ratio of immune killing to net bacterial growth rate. If \( x > 1 \) then the immune response can control the infection and the bacteria reach a maximum population at a time

\[ t_{\text{max}} = \frac{1}{\mu} \ln \frac{x}{x - 1}, \]

depending on the persistence of the immune response, \( 1/\mu \). If bacterial growth is logistic, i.e. \( \lambda(N) = \lambda(1 - K/N) \) clearance is also possible provided \( x > 1 \). Where the immune response proliferates in response to the total bacterial population we assume a saturating response of the form

\[ A(N) = A_0 + \frac{aLN}{b + \phi N}, \]

where \( a \) is the maximum per capita proliferation rate, \( b \) is the bacterial population which gives half the maximum rate and \( \phi \) determines the form of proliferation (\( \phi = 0, 1 \) with saturation when \( \phi = 1 \)). Where resistant strains are also present \( N = N_s + N_r \). If some fitness cost is associated with resistance (e.g. reduced growth rate, \( \lambda' \leq \lambda \)), the full model takes the form

\[ \frac{dN_s}{dt} = \lambda N_s - \alpha(C,MIC_r) N_s - \gamma LN_s, \]

\[ \frac{dN_r}{dt} = \lambda N_r - \alpha(C,MIC_r) N_r - \gamma LN_r, \]

\[ \frac{dI}{dt} = A(N) - \mu I. \]

Numerical evaluation of these equations (figure 4) shows that for self-limiting infections the overall immune response, \( I(t) \), will be determined by both the degree of resistance (measured by MICr) and the time elapsed before treatment begins. For example, early treatment will reduce the total bacterial population, \( N \) (i.e. morbidity), and, in doing so, the resulting immune response (thereby increasing susceptibility to subsequent infections). The reduction in immunity, which is what clears highly resistant strains, will also produce a proportionately more resistant infection (albeit with reduced morbidity), which may have transmission consequences for other hosts. These consequences will be discussed in greater detail in §5.

3. TRANSMISSION DYNAMICS OF ANTIBIOTIC RESISTANT PATHOGENS IN HOSPITALS

The continued evolution of antibiotic resistance in common hospital pathogens presents an ever-increasing threat to public health. Organisms once considered of low invasive potential now give cause for concern in immuno-

Figure 4. Within-host dynamic model of self-limiting bacterial infection showing the effects of antibiotic treatment (dashed lines) on bacterial population size and acquired immunity.

Antibiotic treatment produces lower morbidity with lower immunity. Parameters used are: as in figure 1 with \( \lambda' = 1.2 h^{-1}, \gamma = 0.5 h^{-1}, \alpha = 0.2 h^{-1}, b = 10^{5}, \phi = 1, \mu = 0.05 h^{-1}, I_0 = 0.1, N_s(0) = 2 \times 10^3, N_r(0) = 2 \) and \( I(0) = I_0 \).

compromised hosts. The recent emergence of vancomycin-resistant enterococci (VRE) as a nosocomial pathogen is a striking example of this new danger to vulnerable patients. Treatment options are often limited to combining antimicrobials or experimental compounds of unproven efficacy. Other pathogens, such as Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus (MRSA), have also developed multiple resistance and give even greater cause for concern. Reports of MRSA strains with reduced susceptibility to vancomycin (Hiramatsu et al. 1997; Tabaqchali 1997), suggest that unless there is a return to conventional practices of infection control, with its emphasis on reduced transmission, antibiotic therapy may not be possible in the near future for some hospital acquired infections.

Many factors contribute to make hospitals a favourable environment for the development of resistance, not least of which is the broad spectrum of antimicrobials used to treat infection (Tenover & McGowan 1996). Another important factor is the frequent mixing of patients and health-care workers (HCWs)—for whom asymptomatic carriage is a potential threat. Although some emphasis has been placed on the population dynamics of competition between resistant and susceptible bacteria (Massad et al. 1993; Bonhoeffer et al. 1997), little work has been completed to date with regards to the transmission dynamics of resistant infections within frameworks that meld genetics and epidemiology (Austin et al. 1996a; Sehlie et al. 1997). Many hospital pathogens are capable of colonizing patients without inducing overt symptomatic infection. This generated the belief that new hospital outbreaks were a consequence of endogenous activation from patient sources or environmental contamination. However studies of both VRE and fungal pathogens have demonstrated that indirect transmission via the hands of transiently contaminated HCWs is a very important determinant of colonization and infection (Sanchez et al. 1992; Bonten et al. 1996).

(a) Indirect transmission models of colonization

Patients are classified as either uncolonized \( (X_p) \) or colonized \( (I_p) \). Given the rapid turnover in patients and long duration of colonization, once colonized, patients are assumed to remain so for the duration of their stay in the
ward or intensive-care unit (ICU). The number of HCWs is assumed to be fixed \( N_b \), and HCWs are also assumed to be either uncolonized \( X_h \) or transiently colonized \( Y_h \). The transmission dynamics can be described by four ordinary differential equations (figure 5):

\[
\frac{dX_h}{dt} = A - c \mu X_h Y_p - c \phi T_h X_p,
\]

(24)

\[
\frac{dY_p}{dt} = c \mu X_h Y_p + c \phi T_h X_p - c \mu Y_p - c \phi T_h X_p,
\]

(25)

\[
\frac{dX_h}{dt} = -c \mu X_h Y_p + \gamma Y_h,
\]

(26)

\[
\frac{dY_p}{dt} = -\frac{dX_h}{dt}, \quad X_h + Y_h = N_h,
\]

(27)

where \( A \) is the patient admission rate, \( \phi \) the prevalence of colonization at admission, \( D_p = 1/\mu \) the average patient's length of stay (LOS) (typically days), \( c \) is the HCW–patient contact rate, \( b_h \) and \( b_p \) the respective probabilities of transmission from patient→HCW and HCW→patient, and \( D_h = 1/\gamma \) the average duration of transient colonization (typically hours).

Optimal use of available resources frequently requires that available beds be always occupied (i.e. \( X_p + Y_p = N_p = A/\mu \)). Under this assumption the respective colonization prevalences for patients \( y_p(t) = Y_p(t)/X_p \) and HCWs \( y_h(t) = Y_h(t)/N_h \) are determined by the two differential equations:

\[
\frac{dy_p(t)}{dt} = \mu(\phi + R_p y_p(1 - y_p) - y_p),
\]

(28)

\[
\frac{dy_h(t)}{dt} = \mu(R_0 y_p(1 - y_p) - y_h),
\]

(29)

where \( R_0 = b_h c N_p D_p \) and \( R_p = m b_p c N_p D_p \) are the respective HCW–patient and patient→HCW reproductive numbers, and \( m = N_p/N_h \) is the staff–patient ratio (typically 1:1 for ICUs and less for general wards). Because transmission is via patient→HCW→patient, the overall reproductive number for transmission, \( R_0 \), takes the composite form

\[
R_0 = m b_p c N_p^2 D_p D_h.
\]

(30)

The endemic prevalences are given by

\[
y_p^*(\phi) = \frac{R_0 - 1 + \phi R_0 + \sqrt{(R_0 - 1 + \phi R_0)^2 + 4 \phi(R_0 + R_p)}}{2(R_0 + R_p)},
\]

(31)

\[
y_h^*(\phi) = \frac{R_0 b_p^*(\phi)}{R_0 + R_h} + 1
\]

(32)

(figure 6). If new admissions are carefully screened and colonized patients isolated from the ward (i.e. \( \phi = 0 \), the closed system reduces to the Ross–Macdonald model for malaria transmission (Anderson & May 1991), with vector–host ratio \( m \) and biting rate \( a = c N_p \). The endemic solution takes the simple symmetrical form

\[
y_p^*(0) = \frac{R_0 - 1}{R_0 + R_h}, \quad y_h^*(0) = \frac{R_0 - 1}{R_0 + R_p}.
\]

(33)

Where there is a considerable separation in time-scales (as in this instance), there will be a large difference in endemic prevalences. Typically \( R_p \gg 1 \) and \( R_h \ll 1 \), only the product \( R_0 = R_h R_p \) must be greater than unity for transmission. Therefore in endemic settings the model predicts that \( y_p^* \gg y_h^* \), providing one explanation of the observational finding that culturing the hands of HCWs seldom provides pathogen isolates (Morris et al. 1995).

(i) Hand-washing

Hand-washing by HCWs between patient contacts reduces the probability \( b_h \) that they will transmit the pathogen to their next patient. If \( p \) is the efficacy of hand-washing protocols (equal to the compliance rate times the efficacy/wash), then \( R_0(p) = (1 - p) R_0 \). Transmission can be curtailed (and colonization eradicated) provided \( R_0(p) < 1 \), i.e. if \( p \) exceeds the threshold rate \( p_c = 1 - 1/R_0 \) and new admissions are screened (\( \phi = 0 \)). Even if washing hands is 100% effective, the threshold compliance rate can be very high for modest values of \( R_0 \). Studies show reported compliance rates of 20–40% (Albert & Condie 1981; Simmons et al. 1990; Doebbling et al. 1992). If \( R_0(p) \) is in excess of 1.25–1.67, hand-washing measures alone are unlikely to be sufficient for controlling endemic transmission.
(ii) Management of HCWs

Introducing more HCWs into a ward can either reduce or increase transmission levels, depending upon the management of the ward. Where HCW resources are limited, increasing the number of HCWs will increase transmission due to an increased number of contacts between HCWs and patients. Conversely in the ICU, where resources are less limited, increasing the numbers of HCWs reduces transmission because individual staff workloads are reduced. Cohorting HCWs on a 1:1 basis can provide a very effective method of limiting transmission. If \( q \) is the conditional probability that a HCW returns to the same patient rather than visiting another patient, then the effective HCW–patient ratio \( m(q) = m(1 - q) \). Using the same argument as above, there is a threshold cohorting rate \( q_c = 1 - 1/R_h \). Effective measurement of cohorting rates have yet to be reported. However given that 1:1 HCW–patient ratios are not unusual in ICU settings, cohorting rates are likely to exceed those of hand-washing providing a possible focus for resource allocation (figure 7).

(b) Stochastic considerations

Since the number of HCWs and patients is typically small (less than 30) in most hospital settings, stochastic fluctuations will play an important role in determining the course of an outbreak. When modelling any single outbreak a full stochastic realization of equations (24)–(27) is required (Renshaw 1991; Anderson & May 1991) (figure 8a). Where there is a significant separation of time-scales and the number of patients remains constant, the quasi-steady state (QSS) approximation \((dN/dt \simeq 0)\) can be used to reduce equations (24)–(27) to

\[
\frac{d\psi}{dt} = \phi \mu + \frac{\mu R_h \psi(1 - \psi)}{1 + R_h \psi} - \mu \psi.
\]

An explicit closed solution of this equation is only possible in the limit \( R_h \psi \rightarrow 0 \), which is the logistic equation with immigration of new infectives (Appendix A). In the absence of colonized admissions \((\phi = 0)\) the quasi-equilibrium probability distribution \( \pi_i \), that \( i \) patients will be endemically colonized, can be calculated (figure 8b). Smaller wards and ICUs with few beds will have large fluctuations in prevalence. For example, if \( R_h = 2 \) and \( N_p = 9 \) beds, the predicted 95% confidence region for \( y_p^* \) is \( y_p^* \approx 38.9 \pm 46.2\% \). The magnitude of fluctuations when patient numbers are small implies that identifying trends in endemic settings, perhaps induced by changes in management practices, will be very difficult.

(c) The emergence of resistance

The previous theoretical framework of indirect transmission is equally applicable to both antibiotic-sensitive and -resistant pathogens. However, it does not take into account any measure of the selection pressure exerted by antibiotic treatment. When more than one bacterial strain is present the framework must be modified accordingly to reflect all available therapy combinations. For analytical simplicity we retain the QSS approximation and take the limit \( R_h \rightarrow 0 \) in the closed model of equation (34).

Within an ICU, the majority of patients will receive an antibiotic, either as prophylaxis (e.g. digestive decontamination) or for the treatment of overt infection (e.g. vancomycin for staphylococcal wound infections). Antibiotic therapy may select for resistance by either of two mechanisms. First, treatment may induce or select pre-existing resistant organisms within a host (so-called acquired resistance). Second, by killing off the existing host flora, antibiotic treatment increases the susceptibility to colonization by resistant bacteria. Patients who become colonized with resistant flora may then develop overt...
infection and subsequently have an increased LOS, which in turn increases opportunities for further transmission. Earlier work on antibiotic management has focused on the effects of treatment on reducing durations of infection, as might be expected for upper respiratory tract infection (Massad et al. 1993; Bonhoeffer et al. 1997). We use a similar framework to focus on the effects in ICU settings.

(i) Single drug therapy

We begin by considering the case when only a single antibiotic (or class of antibiotics if resistance patterns are common) is in use. Using the QSS approximation and assuming that all admitted patients are uncolonized (\( \phi = 0 \)), the prevalence of colonization for sensitive (\( f' \)) and resistant (\( f'' \)) strains are determined by the equations

\[
\frac{df'}{dt} = \mu f' (R_0 (1 - f' - f'') - 1) - \mu a \sigma f',
\]

\[
\frac{df''}{dt} = \mu f'' (R_0 (1 - f' - f'') - 1) + \mu a \sigma f',
\]

where \( a \) is the proportion of patient stay for which antibiotics are administered, \( \sigma \) the probability of acquired resistance during treatment and primes denote parameters for the resistant strain. Switching parameters, let \( y \) denote the prevalence of colonization (\( y = f' + f'' \)) and \( f \) the frequency of resistance (\( f = f'' / y \)), then

\[
\frac{dy}{dt} = \left[ \mu R_0 (1 - f) + \mu' R_0' f \right] (1 - y) - \mu (1 - f) - \mu f',
\]

\[
\frac{df}{dt} = f (1 - f) \left[ \mu (R_0 - R_0') (1 - y) + \Delta \mu \right] + (1 - f) \mu a \sigma,
\]

where \( \Delta \mu = \mu - \mu' \geq 0 \). If transmission is unaffected by antibiotic treatment (e.g. infection control practices limit the spread of both strains), \( df / dt \) can be solved exactly. If \( f_0 \) is the frequency of resistance at time \( t_0 \), \( f \) is determined by the logistic solution,

\[
f(t) = \left( f_0 + e \right) \exp(\Delta \mu (1 + e) (t - t_0) - e (1 - f_0)) \]

\[
(1 - f_0) + \left( f_0 + e \right) \exp(\Delta \mu (1 + e) (t - t_0)).
\]

The parameter \( e \) measures the selective pressure of acquired resistance (since there is no difference in transmission) and is determined by \( e = a \sigma (1 + q) / q \), where \( q \) is the percentage increase in LOS for resistantly colonized patients \( (q = (D_0' - D_0) / D_0) \). In the limit \( \sigma = 0 \) (no acquired resistance), if \( f_0 > 0 \) then \( f \rightarrow 1 \) and resistance will tend to fixation at a rate independent of antibiotic treatment. This is simply a consequence of resistantly colonized patients remaining in the ICU longer and therefore having a higher reproductive number \( (R_0 > R_0') \).

The characteristic time-scale for the ecological replacement of sensitive colonization is of order \( 1 / \Delta \mu \), irrespective of antibiotic consumption. Where antibiotic treatment induces acquired resistance and no resistance is present at time \( t_0 \), the time for resistance to reach 50% of cases, \( T_{50} \) is given by

\[
T_{50} = \frac{\ln(2 + 1 | e |)}{\Delta \mu (1 + e)}. \tag{40}
\]

Typically if \( D = 7 \) days, \( q = 25% \ (D' = 1.25 D) \), \( a = 80% \) of patient stay and \( \sigma = 10% \), then \( e = 0.04 \) and \( \Delta \mu = 0.0286 \) week\(^{-1} \), giving \( T_{50} = 48 \) days. Halving antibiotic consumption increases \( T_{50} \) to 59 days, demonstrating that ecological replacement of sensitive colonization is playing a dominant role.

The selective transmission advantage antibiotic-resistant strains have is likely to play a considerable role in the overall emergence of resistance. If LOS is unaffected by antibiotic treatment (i.e. \( \Delta \mu \simeq 0 \)) and acquired resistance minimal (\( \sigma = 0 \)), then

\[
\frac{df}{dt} = \mu f (1 - f) (R_0 - R_0(a)) (1 - y), \tag{41}
\]

where the reproductive number for resistant strains is unaffected by antibiotic treatment. For sensitive strains, antibiotic treatment reduces the probability of acquisition, \( b_y \) during treatment. Hence if \( q \) is the percentage reduction in \( b_y \) during treatment, \( b_y(a) = (1 - a) b_y + a (1 - q) b_y = b_y (1 - q a) \). Therefore \( R_0(a) = (1 - q a) R_0 \) and resistant strains will have a selective advantage provided \( R_0 > R_0(a) \) or equivalently;

\[
a \geq \frac{1 - R_0'(R_0)}{q} \tag{42}
\]

Once this threshold is breached, resistance will increase logarithmically until fixation. If \( y(0) = 1 - 1 / R_0(a) \) is the initial endemic prevalence of colonization, and \( f_0 \simeq 1 / N_y \) (one resistant patient) then

\[
T_{50} \simeq \frac{D_0 \ln (N_y - 1)}{R_0 - R_0(a)}. \tag{43}
\]

As an example, if \( R_0 = R_0(0) \) in the absence of antibiotic therapy, then equation (42) is always satisfied and resistant strains will always have a selective advantage. Therefore, \( R_0 - R_0(a) = a q R_0 \), implying that if antibiotic consumption is halved then the time to reach 50% resistance \( (T_{50}) \) will double.

(ii) Multiple drug policies

Introducing a second antibiotic (or class of antibiotics) provides a greater scope for the management of the evolution of drug resistance. Sensitive infections can be treated with a choice of drug, but more importantly patients with resistant organisms can also be treated effectively. If two drugs are in use then four possible resistance patterns are possible, sensitive (\( f'' \)), resistant to drug 1 (\( f' \)), resistant to drug 2 (\( f'_0 \)) and resistant to both drugs (\( f''_0 \)). Increasing the number of antibiotics gives a maximum of \( 2^k \) resistance patterns for \( k \) drugs used. Retaining the constant population size and QSS approximations, the model for two antibiotics takes the form

\[
\frac{df'}{dt} = \mu f' (R_0 (a_1 a_2) (1 - y) - \mu (a_1 a_2) y), \tag{44}
\]

\[
\frac{df''}{dt} = \mu f'' (R_0 (a_2) (1 - y) - 1) + \mu a_1 a_2 y - \mu a_1 a_2 y', \tag{45}
\]

\[
\frac{df'_0}{dt} = \mu f'_0 (R_0 (a_1) (1 - y) - 1) + \mu a_2 a_2 y - \mu a_1 a_2 y', \tag{46}
\]
where $y^i = y^{i_0} + y^{i_1} + y^{i_2}$, $a_i$ denotes the consumption of drug $i$, $\sigma_i$ the rate of acquired resistance and we have assumed that antibiotic treatment has no effect for patients with multiply resistant organisms. Competition for susceptibles $(1 - y)$ means that the strain with the highest effective reproductive number will eventually dominate, i.e. $y(t) \to 1 - 1/\max(R_0(a_1, a_2), R_0(a_2), R_0(a_1), R_0)$. The overall selection balance will be determined by precisely how the two drugs are used and whether antibiotic resistance confers a reduced transmission success. If antibiotic treatment is 100% effective in reducing colonization (i.e. $q = 1$) then $R_0(a_2) = R_0(1 - a_2)$ and $R_0(a_1) = R_0(1 - a_1)$. The precise influence on $R_0(a_1, a_2)$ depends on how the drug is used. If a single drug treatment is used then $R_0(a_1, a_2) = R_0(1 - a_1 - a_2)$ with $a_1 + a_2 \leq 1$. If, however, multiple antibiotics are used $a_1 + a_2$ may be greater than unity and we take the maximal form $R_0(a_1, a_2) = R_0(1 - \max(a_1, a_2))$.

Figure 9 shows examples of intervention drug use strategies. Sequential drug use, whilst retaining the second antibiotic solely for resistant infections provides a good method of retaining overall efficacy at the risk of multiple resistance. This policy is, however, determined by the rate of acquired resistance for each drug, the effectiveness of rotating antibiotics at regular intervals depends on the period of rotation; too frequent and resistance has no time to decline, too infrequent and resistance may reach endemic levels. It has been argued that the most efficient policy is to use multiple therapy for all patients (Bonhoeffer et al. 1997). This has the advantage that the risk of acquired resistance will be much lower (since singly resistant strains are removed and multiple resistance unlikely). However, this brings complications of cost and possible side effects. Provided multiply resistant patients can be effectively isolated (i.e. $R_0^* \simeq 0$, e.g. by removal from the ICU), careful management of resistance is possible using both interventionist (e.g. cycling) and non-interventionist (e.g. combination) policies.

4. EPIDEMIC SPREAD OF HOSPITAL OUTBREAKS OF MRSA AND VRE

(a) Transmission model

The rapid dissemination of multiply resistant strains of methicillin-resistant *Staphylococcus aureus* (MRSA) and vancomycin-resistant enterococci (VRE) presents new challenges to the treatment of hospital-acquired infection. In England and Wales the number of hospitals affected by epidemic MRSA has increased from 40 per month in 1993 to more than 100 per month in 1997 (PHLS 1997). In New York City the transmission of VRE between hospitals led to 38 out of 81 hospitals reporting VRE outbreaks within three years (Frieden et al. 1993). The recent emergence of VRE in hospitals in the UK is of particular concern since vancomycin use is restricted to the treatment of MRSA and other multiply resistant infections. Nevertheless, epidemic strains of VRE were first detected in the UK in 1987, and as recently as 1995, were detected in 47 hospitals (including 27 for the first time) (PHLS 1996).

In many instances hospital outbreaks have proved both expensive (in associated costs) and difficult to eradicate, requiring careful surveillance and effective infection control measures (Cookson 1995; Boyce et al. 1995; Shay et al. 1996; Cox & Conquest 1997). Each case of MRSA in England and Wales was estimated to carry an additional cost of £2500 in increased patient stay and additional antimicrobial treatment (Mehlar 1993). The longer an outbreak persists, the greater the likelihood that it may spread between wards and eventually to other unaffected hospitals or into the community. Reductions in the duration of outbreaks and the transfer of colonized or infected patients are therefore of the utmost importance during the early stages of an epidemic, where greatest impact can be achieved.

Since epidemiological data on hospital outbreaks of VRE and MRSA are presently only available at a hospital level (rather than number of patients affected), we begin with an epidemiological framework in which hospitals are classified as either unaffected (susceptible) or having a confirmed outbreak (infectious). In the immediate period post-outbreak, a hospital may be on increased alert and less susceptible to subsequent outbreaks (recovered—immune), although such effects are likely to be small. Outbreaks arise as a consequence of either de novo spontaneous introduction, perhaps from a
background source such as a nursing home or the community, at a per capita rate $\sigma$, or by the transfer of colonized patients and staff between institutions. Once confirmed, an outbreak persists for an average duration $D$ days, with eradication rate $\gamma = 1/D$. We assume that the total number of hospitals remains constant for the duration of the epidemic. If $n(t)$ denotes the number of affected hospitals at time $t$, and $N$ is the total number of hospitals, then $n(t)$ is determined by the differential equation

$$\frac{dn(t)}{dt} = \sigma(N - n) + \beta n(N - n) - \gamma n. \quad (48)$$

The transmission parameter, $\beta$, incorporates the prevalence of colonization in the source hospital, the transfer rate between hospitals and the probability of establishing an outbreak in the unaffected hospital. Equation (48) is the closed SIS model with immigration of infectives (see Appendix A) and can be rewritten in terms of two new parameters; growth rate, $r = \beta N - (\gamma + \sigma)$ and carrying capacity, $K = r/\beta$,

$$\frac{dn(t)}{dt} = \sigma N + r n(1 - n/K). \quad (49)$$

Data suggest that spontaneous outbreaks are rare for MRSA (PHLS 1997; Austin & Anderson 1999), and we take the limiting approximation $\sigma \rightarrow 0$, to obtain the well-known logistic solution $n(t) = \frac{K n_0 \exp (r(t - t_0))}{n_0 \exp (r(t - t_0)) + K - n_0}$. (50)

It is helpful to make the transformation from ecological parameters, $r$ and $K$, to epidemiological parameters, $R_0$ and $D$, where $R_0 = \beta ND$ is the number of secondary outbreaks generated by the first primary outbreak, such that $R_0 = N/(N - K)$ and $rD = K/(N - K)$.

Once an epidemic has begun to take off, stochastic fluctuations during the exponential phase are not very important. However, as the number of affected hospitals approaches the endemic state ($n = K$) fluctuations away from the endemic state become significant, and it is important to evaluate their magnitude (Appendix A).

Surveillance programmes and infection control practices can reduce both the transmission parameter $\beta$, and outbreak duration $D$. Fractional changes in these key parameters give corresponding changes in growth rate and carrying capacity such that,

$$\frac{\Delta r}{r} = \left(1 + \frac{1}{rD}\right) \frac{\Delta \beta}{\beta} + \frac{1}{rD} \frac{\Delta D}{D},$$

$$\frac{\Delta K}{K} = \frac{(N - K)}{K} \left(\frac{\Delta \beta}{\beta} + \frac{\Delta D}{D}\right). \quad (51)$$

Reductions in either transmission parameter or outbreak duration will therefore be equally effective in the long-term reduction in carrying capacity. However, reductions in transmission produce greater short-term reductions in growth rate and lower incidences of new outbreaks.

(b) **EMRSA-15 in England and Wales**

Epidemic strains of MRSA are colonizing hospital patients throughout England and Wales (PHLS 1997). Strain EMRSA-15 has become widely disseminated and now accounts for over 100 affected hospitals per month. Assuming de novo introductions are infrequent ($\sigma \approx 0$), maximum-likelihood techniques can be used to estimate the three unknown parameters; $r$, $K$ and $n_0 = n(1993)$. Assuming a total of $N = 400$ hospitals are at risk, the log likelihood, $l$ is given by

$$l(r,K,n_0) = \frac{1}{N} \sum n_i \log(n(t_i)/N + (N - n_i)) \times \log((1 - n(t_i))/N), \quad (52)$$

$$\chi^2 = 2I_{data} - l(r,K,n_0)), \quad (53)$$

where $n_i$ is the number of reported outbreaks at time $t_i$ and $i$ is summed over all available data points. Maximizing $l(r,K,n_0)$ gives $r = 1.08$ yr$^{-1}$ ($95\%$ CI 0.94–1.20); $K = 158$ hospitals ($95\%$ CI 143–173) and $n(1993) = 13.2$ ($95\%$ CI 10.8–15.6) hospitals ($\chi^2 = 42.34$, $\nu = 48$ d.f., $P = \Gamma(\frac{1}{2\chi^2})^2/\Gamma(\frac{1}{2\nu})^2 \approx 0.703$) (figure 10a). Converting to epidemiological parameters, $R_0 = 1.66$, with an average outbreak duration, $D = 219$ days. These results serve to highlight both the rapid spread and, more importantly, persistence of EMRSA-15. Once the endemic state is reached, stochastic fluctuations of up to $\pm 30$ either side of $K$ are predicted with fluctuation index $\sigma_K^2/K = 1.54$ (figure 10b).
Model refi nements

(i) Hospital size

Heterogeneity in hospital size and organization may have considerable infl uence on the transmission dynamics. Subdividing hospitals by size, let \( N_k \) denote the total number of hospitals with \( k \) beds (\( k \) may denote a subclass) and \( n_k \) the number with outbreaks. Then \( N = \sum_k N_k \) and the number of hospitals with \( k \) beds reporting outbreaks will be

\[
\frac{dn_k(t)}{dt} = \sigma_t(N_k - n_k) + \lambda_k(n_k - n_k) - \gamma n_k, \tag{54}
\]

where \( \lambda_k = \sum_i \beta_{ik} h_i \) is the force of infection and \( \beta_{ik} \) the transmission parameter from a hospital with \( i \) beds to one with \( k \) beds. Assuming that \( \lambda_k \) scales with size \( (i.e., \lambda_k = k \lambda \) or equivalently \( \beta_{ik} = k \beta(k) \)) whilst outbreak duration \( D \) remains constant, at endemic equilibrium \( \lambda \) satisfies (Anderson & May 1991)

\[
1 = \frac{1}{k^2} \sum_k \frac{\beta K_k}{\gamma + \lambda_k}. \tag{55}
\]

The reproductive number \( R_0(k) \) is obtained in the limit \( \lambda \to 0 \), hence

\[
R_0(k) = \frac{\beta ND(k^2)}{(k^2)}. \tag{56}
\]

The reproductive number can be significantly greater than the mean behaviour if the standard deviation \( \sigma^2 = (k^2) - (k)^2 \) is much greater than the mean \( (k) \). So-called ‘superspreading hospitals’ can therefore play a disproportionate role. For England and Wales hospitals are graded by NHS trust size (data not shown), rather than number of beds and are accurately described by a truncated normal distribution of the form

\[
p(x) = \frac{\exp \left( -\frac{(x - \mu)^2}{2\sigma^2} \right)}{\sigma \sqrt{\pi/2} \left( 1 + \text{erf}(\mu/2\sigma) \right)}, \tag{57}
\]

where \( p(x) \) is the probability a hospital will have \( x \) beds, \( \mu = 432.5 \) and \( \sigma = 410.7 \). The corresponding mean available beds per trust is \( \bar{x} = 542.7 \) with variance \( \sigma^2 = (\bar{x})^2 - \bar{x}^2 = 108862 \). Using this classifi cation gives \( R_0(k) = 1.39R_0 \), if \( D \) remains constant or \( R_0(k) = 2.32R_0 \) if \( D \) also scales with trust size (Austin & Anderson 1999).

(ii) Spatial spread

The simple model of hospital–hospital transmission can be adapted spatially via either multiple patches (e.g. regional health authorities) (Lloyd & May 1996) or random diff usion (Shigesada & Kawasaki 1997). Let \( n(x,t) \) denote the density of affected hospitals at time \( t \) and coordinate \( x = (x,y) \). The random diff usion model of epidemic spread in two dimensions is expressed as

\[
\frac{\partial n(x,t)}{\partial t} = \sigma \Delta n(x,t) + \beta n(x,t) - \gamma n + A \nabla^2 n, \tag{58}
\]

where \( A \) is the diff usion coe cient. Exact solution of this equation is not possible, although approximation of the exponentially growing phase with \( \sigma = 0 \) gives the radial solution

\[
n(r,t) = \frac{n_0}{4\pi A t} \exp \left( \frac{(R_0 - 1)t}{D} - \frac{r^2}{4A} \right). \tag{59}
\]

5. Antimicrobial resistance in the community

Although hospitals are rightly viewed as so-called ‘hot zones’ where selection of multiply resistant strains is most common, the bulk of antibiotic consumption occurs in the community. As already demonstrated, the primary selection pressure driving changes in the frequency of resistance is the volume of drug use. Establishing a precise quantitative relationship between antibiotic consumption and the frequency of resistance in community settings has been difficult due to the lack of longitudinal studies that record both resistance and consumption patterns (Nissinen et al. 1995; Arason et al. 1996; Seppälä et al. 1997). In a study by Nissinen et al. (1995) in Finland following the rapid emergence of \( \beta \)-lactamase resistance in \textit{Moraxella catarrhalis}, increasing \( \beta \)-lactam consumption led to further increases in the frequency of \( \beta \)-lactamase producing clinical isolates. Many bacterial species, such as \textit{Escherichia coli}, \textit{Haemophilus influenzae}, \textit{Neisseria meningitidis}, \textit{Moraxella catarrhalis}, \textit{Streptococcus pneumoniae} and \textit{Staphylococcus aureus}, exist as commensals in their human hosts with asymptomatic colonization. Arason et al. (1996) considered how the rates of carriage and resistance of \textit{S. pneumoniae} in children in day-care centres were linked to antimicrobial consumption. Reductions in selection pressure will lead to reductions in resistance, although the time-scales may be considerable. In Finland, reducing macrolide consumption appears to have led to reductions in the frequency of macrolide resistance in \textit{S. pneumoniae} (Seppälä et al. 1997). Each of the studies has measured both antibiotic resistance and selection pressure, providing an opportunity to characterize the relationship between carriage, consumption and resistance.

(a) A model of bacterial carriage and antibiotic consumption

Few theoretical frameworks have examined the coupling between population genetics, transmission dynamics and antibiotic consumption (Austin et al. 1997, 1999; Levin et al. 1997). We begin by proposing a simple mathematical framework in which a population of human hosts experience colonization by a directly transmitted commensal organism (such as \textit{S. pneumoniae} or \textit{H. influenzae}). Antibiotic treatment is assumed to be prescribed independently of colonization in response to overt infection by
other strains or species that induce morbidity. In the absence of 'resistant' strains (where resistance will be more clearly defined later), hosts fall into one of four classes: untreated-uncolonized (x), untreated-colonized (X), treated-colonized (Y) and treated-uncolonized (T) (figure 11). The prevalence of each of these classes is determined by the differential equations;

\[
\frac{dx(t)}{dt} = A - \beta x(y + T) - \alpha x + \gamma X + \lambda y - \mu x,
\]

\[
\frac{dy(t)}{dt} = \beta x(y + T) - \alpha y + \gamma Y - (\lambda + \mu)y,
\]

\[
\frac{dX(t)}{dt} = \alpha(x + (1 - \sigma)x)f\beta X(y + T) + \lambda Y - (\lambda + \mu)X,
\]

\[
\frac{dY(t)}{dt} = \alpha \sigma y + \phi \beta X(y + T) - (\gamma + \lambda + \mu)Y,
\]

where \(\alpha\) is the prescribing rate (per unit time), \(1/\gamma\) the average length of treatment (typically days) and \(\sigma\) the probability that treatment does not clear colonization. The transmission dynamics of colonization are determined by \(\beta\), the rate commensals are spread to other hosts, \(\phi\) the protection afforded by treatment and \(1/\lambda\) the average duration of colonization (typically months). Demographics are described by \(A\), the per capita birth–immigration rate and \(1/\mu\) the average duration hosts remain in the community. For children in day-care centres and the elderly in nursing homes it may be comparable with \(1/\lambda\). For analytical simplicity we assume that the number of hosts is fixed (i.e. \(A = \mu h\)), hence \(x + y + X + Y = 1\) at all times. The basic reproductive number is given by \(R_0 = \beta /\lambda\), where \(X = \lambda + \mu\). In the absence of antibiotic therapy, a commensal can cause an epidemic with probability \(1 - 1/R_0\) and will become established with endemic prevalence \(p = y^* = 1 - 1/R_0\).

\(\text{Figure 11. Mathematical framework for bacterial colonization by directly transmitted organisms incorporating the effects of antibiotic consumption. Antibiotics are prescribed to a proportion, } a, \text{ of the population and are assumed to clear colonization in a proportion } (1 - \sigma) \text{ of treated hosts (see text for equations).}\)

\(\text{other strains or species that induce morbidity. In the absence of 'resistant' strains (where resistance will be more clearly defined later), hosts fall into one of four classes: untreated-uncolonized (x), untreated-colonized (X), treated-colonized (Y) and treated-uncolonized (T) (figure 11). The prevalence of each of these classes is determined by the differential equations; }\)

\(\text{where } \alpha \text{ is the prescribing rate (per unit time), } 1/\gamma \text{ the average length of treatment (typically days) and } \sigma \text{ the probability that treatment does not clear colonization. The transmission dynamics of colonization are determined by } \beta, \text{ the rate commensals are spread to other hosts, } \phi \text{ the protection afforded by treatment and } 1/\lambda \text{ the average duration of colonization (typically months). Demographics are described by } A, \text{ the per capita birth–immigration rate and } 1/\mu \text{ the average duration hosts remain in the community. For children in day-care centres and the elderly in nursing homes it may be comparable with } 1/\lambda. \text{ For analytical simplicity we assume that the number of hosts is fixed (i.e. } A = \mu h, \text{ hence } x + y + X + Y = 1. \text{ The basic reproductive number is given by } R_0 = \beta /\lambda, \text{ where } X = \lambda + \mu. \text{ In the absence of antibiotic therapy, a commensal can cause an epidemic with probability } 1 - 1/R_0 \text{ and will become established with endemic prevalence } p = y^* = 1 - 1/R_0.\)

\(\text{Consumption of antibiotics is conventionally measured in defined daily doses per 1000 adults (DDDs/1000), equivalent to the proportion of the community, } a = X + Y, \text{ receiving treatment at any time. For adults, the equivalence is good and } a \geq 0.5 - 1% \text{; however, for children, where doses depend on age and consumption is much greater } (a \simeq 5%\text{), the equivalence is poor (Austin et al. 1999). For a constant population size, } a \text{ is determined by }\)

\[
\frac{da(t)}{dt} = -\alpha + \gamma + \mu) a,
\]

which has the general solution

\[
a(t) = \frac{\alpha}{\alpha + \gamma + \mu} (1 - \exp(- (\alpha + \gamma + \mu)t)).
\]

Since typical treatment times are short compared to colonization (\(\gamma \gg \lambda\)), \(a\) rapidly reaches the equilibrium value \(a \simeq \alpha /\gamma\) or equivalently; prescribing rate multiplied by length of treatment. The simple assumptions about the nature of antibiotic treatment lead to two endemic extremes, depending on non-clearance rate, \(\sigma\), and reduced susceptibility, \(\phi\).

\(\text{(ii) Antibiotic treatment clears and prevents colonization }\)

Where commensals are fully susceptible to antibiotics, treatment may both clear and prophylactically protect against colonization completely \((\phi = \sigma = 0)\). Increasing antibiotic consumption will therefore reduce the average duration of colonization and the number of hosts who are susceptible. The prophylactic properties of treatment imply that the endemic state is given by

\[
x^* = \frac{1}{R_0} \left(1 + \frac{\delta a}{1 - a}\right), \quad y^* = 1 - a - x^*, \quad X^* = a, \quad Y^* = 0,
\]

where \(\delta = (\mu + \gamma) / (\mu + \lambda)\) is the ratio of length of colonization to length of treatment (typically \(\delta \gg 1\)). Eradication of a commensal from a population is possible provided \(y^* \leq 0\), or equivalently \(a \geq a_c(p)\) where \(p\) is the prevalence without treatment \((p = 1 - 1/R_0)\), and the threshold consumption is given by

\[
a_c(p) = \frac{1}{2} \left( p + 1 + \delta(1 - p) - \sqrt{(p + 1 + \delta(1 - p))^2 - 4p}\right).
\]

For example, when 50% of hosts are colonized and \(\delta = 4\), a threshold \(a_c = 15%\) of hosts must be treated at any time (figure 12). Since \(a\) is typically much less than 100% and \(\delta\) large, to \(O(a)\),

\[
a_c \simeq \frac{p}{1 + \delta(1 - p)} = \frac{R_0 - 1}{R_0 + \delta},
\]

giving \(a_c = 1/6\) for the previous estimate.

\(\text{(c) Antibiotic treatment has no effect on colonization }\)

Should antibiotic treatment leave colonization unchanged \((\phi = \sigma = 1)\) (which may be the case where a commensal is fully resistant or an antibiotic has very high specificity and does not reach the colonization site), there is an absolute separation between consumption and carriage such that

\[
x^* = (1 - a) / R_0, \quad y^* = (1 - a) (1 - 1/R_0),
\]

\[
X^* = a / R_0, \quad Y^* = a(1 - 1/R_0).
\]

Where antibiotic consumption is low, treated-colonized hosts \((T)\) always form a very small fraction of the whole.

\(\)
commensals require extensive treatment rates for elimination. Colonization to duration of treatment, where cleared and non-cleared is therefore a function of mean MIC (i.e. mean minimum inhibitory concentration (MIC) can be defined over the whole population. The clearance failure rate must evidently be a function of MIC; low MICs will lead to clearance, high MIC non-clearance. Resistance is classically determined by break points, with the broad distinctions; (S)ensitive, (I)ntermediate or (R)esistant being made. Second, using microsimulation techniques, a population-genetic approach can be used to model the effects of individual hosts. Competing selection takes place within colonized hosts, and the relative fitness of sensitive and resistant strains will be determined by whether individual hosts are receiving treatment (Levin et al. 1997). Finally additional resistant classes can be added to the original framework to include untreated-resistant and treated-resistant colonized hosts (Austin et al. 1997b).

(b) Non-clearance as a function of MIC

We have already seen how the MIC plays an important role in determining the within-host outcome of antibiotic therapy. Where doses maintain antibiotic concentrations above MIC for sufficient periods, clearance of bacteria will result. For commensal organisms, which may colonize other areas of the body aside from the pathogen of interest, the MIC antibiotic concentration may be different but the underlying criterion remains. The rate of non-clearance is therefore a function of mean MIC (i.e. $\sigma(m)$). Since antibiotic activity is well described by the $E_{\text{max}}$ model, the non-clearance rate will also be determined by a saturating function of the form

$$\sigma(m) = \frac{m^*}{m^* + m^*_{50}},$$

where $m^*_{50}$ is the MIC at which only 50% of colonization is cleared and $n$ is a constant determined by the underlying within host pharmacodynamics. If a partial differential equation approach is taken, $x, y, X$ and $Y$ become functions of both time and MIC, such that equations (61)–(64) are replaced by equations of the form

$$\frac{\partial x(m,t)}{\partial t} + \frac{\partial x(m,t)}{\partial m} \frac{dm}{dt} = \frac{1}{\gamma} - \frac{1}{\gamma} \frac{dm}{dt} = \frac{1}{\gamma} - \frac{1}{\gamma} \frac{dm}{dt} = \frac{1}{\gamma} - \frac{1}{\gamma} \frac{dm}{dt}$$

and the frequency of resistance takes the form

$$f(m) = \frac{\int_0^\infty dm' f(y(m',t) + Y(m',t))}{\int_0^\infty dm' f(y(m',t) + Y(m',t))},$$

where $m_r$ is the breakpoint MIC determining resistance. Evolution of the partial differential equation system is determined by the dynamics of the MIC, $dm/dt$. When antibiotic treatment does not clear colonization, but instead selects pre-existing bacteria with increased MIC (so-called acquired resistance), the mean MIC will increase. Any increase must, however, be density-dependent because when the MIC is very large, incremental changes in MIC following treatment failure will be negligible. Increasing MIC may carry additional incremental costs (i.e. reduced fitness) and therefore withdrawal of selection may cause a reversal of MIC with some characteristic time-scale. The rate MIC increases is dependent on the number of hosts who select for increased MIC hence

$$\frac{dm}{dt} = F(m) \int_0^\infty dm' \sigma(m') \alpha(t) y(m',t),$$

where $F(m)$ is a monotonically decreasing function of MIC which incorporates the fact that the increase in $m$ becomes smaller as $m$ becomes large.

Rather than solve the full equations, we make the limiting assumption that only $\sigma$ is a function of $m$, and that $m$ describes the mean MIC in the population as a whole. The principal limitation of this assumption is that all information about the frequency of antibiotic resistance is lost. Equations (61)–(64) remain unchanged with the addition of a further equation for $m$ of the form

$$\frac{dm}{dt} = F(m) \frac{c m^* y(t)}{m^* + m^*_{50}},$$

The system of equations exhibits limiting behaviour when $m \ll m_{50}$ and $m \gg m_{50}$, i.e. $\sigma \simeq m/m_{50}$ and $\sigma \approx 1$, respectively. Immediately after an antibiotic has been introduced $y(0) = y'(a)$ (equation (68)) and any density-dependent effects on MIC increase will be small. If $n = 1$, $m(t)$ takes the exponential form

$$m(t) \simeq m_0 \exp \left( \frac{F(m_0)}{m_0} \right) \alpha/ \sigma,$$

with an MIC doubling time, $\tau_m$ of
Communities with higher colonization rates or antibiotic consumption, will see faster emergence of strains with elevated MICs. Once MICs are above $m_0$, non-clearance becomes much more likely. It is here where density-dependent effects may be more clearly felt. Where there is no effect, $m(t)$ increases linearly with time. When $F(m)$ decreases monotonically, an eventual upper bound is placed on $m$.

Numerical solutions with parameter estimates typical of penicillin-resistant *Streptococcus pneumoniae* (PRP); $R_0 = 2$, $1/\lambda = 2$ months (Christenson et al. 1997), $\alpha = 1$ year$^{-1}$, $1/\gamma = 5$ days ($a = 1.4\%$), $m_0 = 1$ mg ml$^{-1}$, $F(m) = 1$ mg ml$^{-1}$ give a doubling time of approximately two years (figure 13). Exact calculation of $F(m)$ requires detailed longitudinal MIC data which has yet to be made available. Resistant strains of *S. pneumoniae* are characterized by MIC in excess of 1 mg ml$^{-1}$, suggesting that if $m(0) = m_0/100$, PRP carriage will become a problem after 10–20 years of relatively intense selection.

(e) **Explicit resistant classes**

A second way of incorporating resistance is via the introduction of an explicit second commensal strain, which is assumed to either be resistant or at the very least have reduced susceptibility (Austin et al. 1997, 1999a). A further two classes of host are required: untreated-resistant ($Z$) and treated-resistant ($\hat{Z}$). Since antibiotic treatment is assumed to either clear sensitive strains or induce acquired resistance (with probability $\sigma$), the class that is treated-sensitive ($Y$) is redundant. Resistance is again assumed to be associated with some fitness cost, although the precise nature of this cost is in the form of reduced transmission success (measured by $R_0$). Recalling that the reproductive number is the product of transmission rate and duration of carriage, resistant strains may manifest themselves either via reduced transmissibility (lower $\beta$) or increased duration of carriage (higher $\lambda$), or both. A further measure of transmission success is captured in the role of superinfection, i.e. the net probability that a host colonized with a resistant strain will revert to sensitive following contact with other sensitively colonized hosts. Under these assumptions, the two-strain model with antibiotic prescribing takes the form

\[
\frac{dx(t)}{dt} = A - \beta xy - \beta xZ - \alpha x + \gamma X + \lambda y + \lambda Z - \mu x, \tag{79}
\]

\[
\frac{dy(t)}{dt} = \beta xy - \phi yz - (\alpha + \lambda + \mu) y, \tag{80}
\]

\[
\frac{dz(t)}{dt} = \beta xZ - \phi yz - (\alpha + \lambda + \mu) z + \gamma Z, \tag{81}
\]

\[
\frac{dX(t)}{dt} = \alpha(x + (1-\sigma)y) - \phi \beta xZ + \lambda Z - (\gamma + \mu) X, \tag{82}
\]

\[
\frac{d\hat{Z}(t)}{dt} = \alpha(z + \sigma y) + \phi \beta xZ - (\gamma + \lambda + \mu) \hat{Z}, \tag{83}
\]

where $Z = z + \hat{Z}$ and primes denote parameters for resistant commensal strains. In the absence of resistance endemic colonization is again given by equation (68), with the threshold for eradication $a_e$ unchanged.

(i) **Relationship between antibiotic consumption and resistance**

Using the simplifying assumption that antibiotic consumption is low ($a \ll 1$), an approximate solution of the model is possible (Appendix B). If non-clearance rates are zero, two thresholds are defined, $a_2$ for the emergence of resistance and $a_1$ for the eradication of sensitive strains. Parameters used are $R_0 = 2$, $R_0 = 2.6$, $\alpha = 0.43$, $1/\lambda = 1/\lambda = 1.1$ months and $1/\mu = 72$ months. Numerical solution shows the effect of treatment failure when $\sigma = 10^{-2}$.

Changes in antibiotic consumption, $Aa$, will give corresponding changes in resistance, $A f^*(a)$, such that

\[
f^*(a) = \frac{1 - a_2/a}{1 - a_2/a} . \tag{84}
\]
transmission success ($R_0 > R_c$) but be susceptible to superinfection by sensitive strains ($\phi > 0$).

6. DISCUSSION

The series of problems discussed in this paper are broad, ranging from MIC levels within a treated patient to the community-based frequency of drug resistance. In each case mathematical models provide insights into the interpretation of observed pattern and the management of antibiotic resistance. The various models discussed reflect differing degrees of sophistication in terms of the overall goal of melding approaches from pharmacology, microbiology, population genetics and epidemiology. By concentrating first on the within-host dynamics of treatment and expanding into population-based epidemiological models, it is possible to see how the treatment of the individual has implications for the wider population.

Our analyses demonstrate clearly the widely differing proximity of theory with experiment and observation. In some cases, such as the spread and management of antibiotic resistance in an intensive care setting, estimates for the values of key parameters and variables are often available. In other areas, such as the pharmacodynamics of the interaction between specific drugs and specific bacteria, data are sparse (particularly so for resistant organisms). It is surprising that the level of quantification is so high for the pharmacokinetic side, yet so sparse for the pharmacodynamics. Models should help to stress how important such measurements are to the evaluation and management of antibiotic resistance. Specifically, where one or more drugs are used to treat a particular bacterial infection, the design of treatment protocols to minimize the likelihood of the emergence of resistance requires much more precise pharmacodynamic data.

More generally, there are also important gaps in quantification and measurement in the population genetic and epidemiological areas. It again seems surprising that so few studies have provided precise longitudinal data on the frequency of resistance in a well-defined sample of the patient population, and concomitantly, the volume of drug consumption over time in that population. The latter is the strength of selection and its precise measurement is key to the interpretation of how the frequency of resistance changes over time. Related to this issue is the question of sampling. In general, too little thought has been given to date on how best to monitor temporal changes in the frequency of resistance to a particular drug in defined organisms. There is an urgent need for concerted action internationally in this area, given the globally mixing nature of the world's population today and the speed with which antibiotic resistance can spread from one country to another.

Once data are available, the use of mathematical models provides a quantitative tool for possible scenario analysis. An obvious example is the epidemiological spread of multiply resistant bacteria between hospitals. Once the key parameters have been estimated, questions regarding the impact of intervention strategies (such as surveillance and outbreak control) can be addressed in a meaningful way. Understanding the dynamics of the model provides additional information regarding implementation time-scales. For example, theory demonstrates

---

**Figure 15. Prediction of a two-step rise in the frequency of β-lactamase producing isolates of Moraxella catarrhalis (Nissinen et al. 1995). Initial colonization is assumed to be endemic with $Z(0) = 0.002$ and $a = 57.7$ DDDs/1000 children (4%). All other parameters are as in figure 15. The approximate solution (Appendix B) is in good agreement with the numerical results prior to the introduction of cephalosporins in 1986.**

\[
\frac{\Delta f^+}{f^+} = \frac{a_2 - a_1}{a - a_2},
\]

with limits $\Delta a/a = (a_2 - a)/a_2$ for the fixation of resistance and $\Delta a/a = (a - a_2)/a$ for its eradication. Small changes in antibiotic consumption can therefore induce considerable changes in resistance if consumption is sufficiently close to either of the thresholds, $a_2$ or $a_1$.

(ii) Emergence of β-lactamase resistance in Moraxella catarrhalis in Finland

Since 1977 *M. catarrhalis* resistance to β-lactams has increased rapidly in Europe and the USA reaching 80–85% (Berk et al. 1996). Studies in Finland using clinical isolates from otitis media in children aged less than six years show a rapid rise in resistance from 0% ($n = 53$) in 1978 to 57% ($n = 115$) in 1983. During this time β-lactam antibiotic consumption was estimated to have remained roughly constant at 5.5 DDDs/1000 adults ($a = 0.55\%$) (Nissinen et al. 1995). After the introduction of second generation cephalosporins there followed a further 51% increase in β-lactam consumption and an associated rise in β-lactam resistance (figure 15). Parameter estimation is done by minimizing a weighted least squares estimate using multidimensional direction set methods (Press et al. 1992) and numerical realizations of the equations (79)–(83). The approximate solution gives excellent agreement where selection pressure is constant (1978–1985).

Parameter estimates give $a = 3.8\%$ or equivalently 38 DDDs/1000 children, which is in keeping with other estimates of infant antibiotic consumption (Arason et al. 1996). It should be stressed that the parameters are for children less than six years old and that evidently antibiotic consumption in children differs widely from that of the whole community. This non-equivalence presents an important gap in our knowledge. Since children are the largest consumers of antibiotics, conventional measures of consumption fail to estimate the true selection pressure in those with the highest rates of carriage. There is an interplay between transmission success ($R_0/R_c$) and superinfection. Resistant strains may have higher

---

*Phil. Trans. R. Soc. Lond. B* (1999)
that the emergence time-scales for antibiotic resistance will be much greater than that required for decline.

The gaps in data needs are of obvious importance in the development of a robust theoretical framework and all efforts should be made to increase awareness of their existence. Indeed, one of the key roles of mathematical model development in infectious disease research is the identification of what needs to be measured to further understanding and better organize control interventions. In the field of antibiotic resistance, theory will certainly fill this role. However, it is important to recognize that even in the absence of a good observational database, theory also helps to interpret observed patterns, facilitate the development of better management practices and create a template for interdisciplinary research. The latter is of particular importance in developing an understanding of how best to slow the evolution and spread of antibiotic-resistant organisms.

D.J.A. and R.M.A. acknowledge the Wellcome Trust for ongoing financial support. Correspondence and requests for materials to D.J.A. (daren.austin@zoology.ox.ac.uk).

**APPENDIX A**

(a) SIS with immigration

If \( a \) is the immigration rate of new infectives, the closed SIS model takes the form

\[
\frac{dn(t)}{dt} = a + \mu R_0(n - n)a/N - \mu n, \tag{86}
\]

or equivalently

\[
\frac{dn(t)}{dt} = a + rn - sn^2, \tag{87}
\]

with growth rate \( r = \mu (R_0 - 1) \) and carrying capacity \( K = N(1 - 1/R_0) = r/s \). Completing the square and factorizing,

\[
\frac{dn(t)}{dt} = s(K_1 + \phi) - (n - K_1 + \phi) + (n - K_1 \phi), \tag{88}
\]

where

\[
1 + \phi = \sqrt{1 + 4a/rK}. \tag{89}
\]

With a change of variables, \( w(t) = n(t) - K_1 \phi \) and \( v = K_1(1 + \phi) \), the general solution is

\[
\log \left( \frac{v + u(t)}{v - u(t)} \right) = \log \left( \frac{v + u(t_0)}{v - u(t_0)} \right) + r(1 + \phi)(t - t_0). \tag{90}
\]

Hence the final solution in terms of \( n(t) \) is obtained by rearranging

\[
n(t) = \left[ (K + \delta K)(n_0 + \delta K) \exp \left( r(1 + \phi)(t - t_0) \right) - \delta K - \delta K - n_0 \right]/(\theta_0 + \delta K) \times \exp \left( r(1 + \phi)(t - t_0) + K + \delta K - n_0 \right), \tag{91}
\]

where \( \delta K = \frac{1}{2} \phi K \). In the limiting case where immigration rates are much smaller than transmission (i.e. \( 4a < rK \)),

\[
\frac{\delta K}{K} \simeq \frac{a}{rK}, \quad \frac{\delta}{r} = \frac{2}{K}. \tag{92}
\]

(b) Stochastic SIS model without immigration

Setting \( a = 0 \), the stochastic version of the SIS model can be written in terms of a probability equation for \( r(t) \), the probability that \( n(t) = i \), such that

\[
\frac{dp_i(t)}{dt} = (i + 1)p_{i+1}(t) + (R_0(i - i/N) - i)p_i(t) - R_0(i - 1)(1 - (i - 1)/N)p_{i-1}(t). \tag{93}
\]

The quasi-equilibrium probabilities, \( \phi_i \), can be obtained after setting \( dp_i/dt = 0 \), hence rearrangement

\[
(i + 1)\pi_{i+1} + R_0(i - i/N)\pi_i = \pi_i + R_0(i - 1)(1 - (i - 1)/N)\pi_{i-1}, \tag{94}
\]

Solution of this difference equation gives

\[
\pi_i = \frac{q_i}{\sum q_j}, \quad q_i = \frac{R_0(i - i/N)}{i + 1} q_i, \quad q_1 = \frac{1}{\mu}. \tag{95}
\]

The average time to extinction from an initial state, \( i \), \( \tau_x(i) \) is approximately (Renshaw 1991) \( \tau_x \simeq \sum q_j \), and for a pure logistic process (birth rate = \( r_0 \), death rate = \( r_0^2/K \)), \( \tau_x \simeq \exp(K/rK) \), with stability index \( \xi = \log(\tau_x) \simeq K \).

The quasi-equilibrium distribution, \( \pi_i \) can be approximated by both normal and negative binomial distributions with stochastic mean, \( \langle K \rangle \), and variance, \( \sigma^2 \),

\[
\langle K \rangle = N \left( 1 - \frac{1}{R_0} \right) - \frac{1}{R_0 - 1}, \quad \sigma^2 = \frac{N}{R_0} \tag{96}
\]

(see Renshaw (1991), chapter 3 for further details). The magnitude of fluctuations is determined by \( \sigma^2/K \). If \( 1 < R_0 < 2 \), the variance will be greater than the mean and fluctuations considerable. Using the normal distribution approximation for \( \pi_n \), the 95% confidence region for the endemic prevalence \( k' = K/N \) is predicted to lie in the range

\[
k' \simeq 1 - \frac{1}{R_0} - \frac{1}{N(R_0 - 1)} \pm 1.96/\sqrt{R_0N}. \tag{97}
\]

Therefore large population sizes and high transmission tend to reduce fluctuations in prevalence, whereas small numbers (e.g. ICUs) may be subject to very large fluctuations. Generalization of the transition region \( R_0 \rightarrow 1 \) has been done by incorporating a reflecting state at rather than the absorbing state \( p_n \) (Nasell 1997). This is perhaps more characteristic of the case where immigration of new infectives is important.

**APPENDIX B. APPROXIMATE SOLUTION OF ANTIBIOTIC CARRIAGE MODEL WITH RESISTANT CLASSES**

If antibiotic consumption is low (\( a \ll 1 \)) and the number of hosts remains constant, then \( \phi(t) \simeq (1 - a) \langle Z(t) \rangle \) and equations (79)–(83) simplify giving

\[
dy/dt = \beta y (a - (1 - a)(Z - y)), \tag{98}
\]
For emergence, typically a single host is initially colonized. If there is no transmission ($\sigma = 0$) can maintain resistant commensals at a frequency $O(\sigma)$, even where there is considerable transmission fitness cost. The full coexisting endemic state, $(y^*, Z^*)$, when $\sigma = 0$, is given by

$$y^*(a) = \frac{y_0(a) - (1 - a)(1 - \phi)(1 - 1/R_0)}{1 - (1 - a)(1 - \phi)(1 + \phi'(1 - a))},$$

$$Z^* = Z_0^* - y^*(a)(1 + \phi'(1 - a)).$$

Coexistence requires $y_0(a) \geq (1 - a)(1 - \phi)(1 - 1/R_0)$ or equivalently $a_Z \leq a \leq a_y$, where in the absence of any cost of resistance ($R_0 = R_0^*$),

$$a_y = \frac{\phi a_y}{1 + \phi}, \quad a_z = \frac{\phi a_z}{1 + \phi}. \quad (101)$$

Using the quasi-steady state approximation (QSSA), $dy/dt \approx 0$, gives the relationship $y(Z) \approx y_0 - Z(1 - a) \times (1 - \phi)$, which after substitution reduces equation (99) to a logistic equation with general solution

$$Z(t) = \frac{A(a) Z_0 \exp \left( A(a) (t - t_0) \right)}{A(a) + B(a) Z_0 \exp \left( A(a) (t - t_0) \right) - 1}. \quad (102)$$

where $A(a) = \beta[1 - 1/R_0 - y_0(a)/(1 + \phi'(1 - a))]$ and $B(a) = \beta[1 - (1 - a)(1 - \phi)(1 + \phi'(1 - a))]$. Hence the frequency of resistance $f(t,a)$ is given by

$$f(t,a) = \frac{\phi A(a) Z_0 \exp \left( A(a) (t - t_0) \right) + y_0(a)}{\phi A(a) + B(a) Z_0 \exp \left( A(a) (t - t_0) \right) - 1}. \quad (103)$$

For emergence, typically a single host is initially colonized (i.e. $Z_0^* \approx 1/N_{\text{host}}$). If there is no transmission fitness cost of resistance, the time to reach 50% resistance, $\tau_{50}$ is

$$\tau_{50} = \frac{1}{\beta \phi Z^* \left( 1 - \phi \right) N_{\text{host}}} \log \frac{y_0(a) Z^* a_y N_{\text{host}}}{Z^*(2 - \phi) - y_0(a)}, \quad (104)$$

where $Z^*(a) = A(a)/B(a)$. In the limit as $t \to \infty$, the endemic frequency of resistance, $f^*(a)$, takes the simple form

$$f^*(a) = \frac{A(a)}{\phi A(a) + y_0(a) B(a)} \left( 1 - a_Z \right) = (a - a_Z) + a_Z \frac{\phi R_0 (R_0 - 1) + (R_0 - R_0^*)(1 - a/a_y)}{\phi R_0 (R_0 - 1) + (R_0 - R_0^*) (1 - a/a_y)}.$$

provided antibiotic consumption lies in the range $a_Z \leq a \leq a_Y$.

REFERENCES


Modelling antibiotic resistance


Roshaw, E. 1993 Modelling biological populations in space and time. Cambridge University Press.


